Spigel D, et al. Impower110: interim overall survival (OS) analysis of a phase 3 study of atezolizumab (atezo) versus platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC. ESMO Congress 2019, abstract LBA78.
Fase II-onderzoek naar oncolytisch coxsackievirus A21 bij niet-resectabel melanoom
nov 2021 | Dermato-oncologie